Design of Topical Moxifloxacin Mucoadhesive Nanoemulsion for the Management of Ocular Bacterial Infections

Ocular bacterial infections can lead to serious visual disability without proper treatment. Moxifloxacin (MOX) has been approved by the US Food and Drug Administration as a monotherapy for ocular bacterial infections and is available commercially as an ophthalmic solution (0.5% <i>w</i>/<i>v</i>). H...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ahmed Adel Ali Youssef, Ruchi Thakkar, Samir Senapati, Poorva H. Joshi, Narendar Dudhipala, Soumyajit Majumdar
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2022-06-01
Edice:	Pharmaceutics
Témata:	ocular bacterial infections moxifloxacin nanoemulsion transcorneal mucoadhesive agent ex vivo
On-line přístup:	https://www.mdpi.com/1999-4923/14/6/1246
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!